Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders"

Konstantinos N. Lazaridis, Gregory J. Gores, Keith D. Lindor

Research output: Contribution to journalReview articlepeer-review

278 Scopus citations

Abstract

UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

Original languageEnglish (US)
Pages (from-to)134-146
Number of pages13
JournalJournal of Hepatology
Volume35
Issue number1
DOIs
StatePublished - Jul 25 2001
Externally publishedYes

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders"'. Together they form a unique fingerprint.

Cite this